Now showing 1 - 10 of 12
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism
    (Lippincott Williams & Wilkins, 2020-05)
    Mehdipoor, Ghazaleh
    ;
    Jimenez, David
    ;
    Bertoletti, Laurent
    ;
    Fidalgo, Ángeles
    ;
    Sanchez Muñoz-Torrero, Juan Francisco
    The choice of the imaging modality for diagnosis of pulmonary embolism (PE) could be influenced by provider, patient or hospital characteristics, or over time. However, little is known about the choice of the diagnostic modalities in practice. The aim of this study was to evaluate the variations in the use of imaging modalities for patients with acute PE.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Upper gastrointestinal bleeding from primary aortoesophageal fistula in a patient with aneurism of the thoracoabdominal aorta: Case report and literature review
    (Wiley, 2024-08)
    ;
    ;
    Andov, Mishel
    ;
    Kolev, Aleksandar
    ;
    Bundovski, Kristijan
    Upper gastrointestinal bleeding due to primary aortoesophageal fistula is a rare clinical condition burdened with high mortality rate. However, the outcomes are closely related to the level of clinical awareness, the complementary and multidisciplinary approach during the diagnostic workup, and the selected treatment option. We present an atypical case of an aneurysm of the thoracoabdominal aorta complicated with primary aortoesophageal fistula (AEF). A 55‐year‐old male with no previous diseases, presented with prolonged and intense back pain and upper gastrointestinal bleeding. The gastroscopy detected an unusual culprit lesion in the distal esophagus resembling an esophageal wall defect, and the computed tomography revealed an aneurysm of the thoracoabdominal aorta, remarkable surrounding hematoma, and active contrast extravasation. Despite the urgent surgical repair, a lethal outcome occurred. AEF patients require high clinical awareness and complementary multidisciplinary approach in order to provide a rapid diagnosis and optimal treatment.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism
    (Elsevier BV, 2018-11)
    Moustafa, Farès
    ;
    Stehouwer, Alexander
    ;
    Kamphuisen, Pieter
    ;
    Sahuquillo, Joan Carles
    ;
    Sampériz, Ángel
    Background: The optimal management of major bleeding in patients receiving vitamin K antagonists (VKA) for venous thromboembolism (VTE) is unclear. Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to assess the management and 30-day outcomes after major bleeding in patients receiving VKA for VTE. Results: From January 2013 to December 2017, 267 of 18,416 patients (1.4%) receiving long-term VKA for VTE had a major bleeding (in the gastrointestinal tract 78, intracranial 72, hematoma 50, genitourinary 20, other 47). Overall, 151 patients (57%) received blood transfusion; 110 (41%) vitamin K; 37 (14%) fresh frozen plasma; 29 (11%) pro-haemostatic agents and 20 (7.5%) a vena cava filter. During the first 30 days, 59 patients (22%) died (41 died of bleeding) and 13 (4.9%) had a thrombosis. On multivariable analysis, patients with intracranial bleeding (hazard ratio [HR]: 4.58; 95%CI: 2.40-8.72) and those with renal insufficiency at baseline (HR: 2.73; 95%CI: 1.45-5.15) had an increased mortality risk, whereas those receiving vitamin K had a lower risk (HR: 0.47; 0.24-0.92). On the other hand, patients receiving fresh frozen plasma were at increased risk for thrombotic events (HR: 4.22; 95%CI: 1.25-14.3). Conclusions: Major bleeding in VTE patients receiving VKA carries a high mortality rate. Intracranial bleeding and renal insufficiency increased the risk. Fresh frozen plasma seems to increase this risk for recurrent VTE.Background: The optimal management of major bleeding in patients receiving vitamin K antagonists (VKA) for venous thromboembolism (VTE) is unclear. Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to assess the management and 30-day outcomes after major bleeding in patients receiving VKA for VTE. Results: From January 2013 to December 2017, 267 of 18,416 patients (1.4%) receiving long-term VKA for VTE had a major bleeding (in the gastrointestinal tract 78, intracranial 72, hematoma 50, genitourinary 20, other 47). Overall, 151 patients (57%) received blood transfusion; 110 (41%) vitamin K; 37 (14%) fresh frozen plasma; 29 (11%) pro-haemostatic agents and 20 (7.5%) a vena cava filter. During the first 30 days, 59 patients (22%) died (41 died of bleeding) and 13 (4.9%) had a thrombosis. On multivariable analysis, patients with intracranial bleeding (hazard ratio [HR]: 4.58; 95%CI: 2.40-8.72) and those with renal insufficiency at baseline (HR: 2.73; 95%CI: 1.45-5.15) had an increased mortality risk, whereas those receiving vitamin K had a lower risk (HR: 0.47; 0.24-0.92). On the other hand, patients receiving fresh frozen plasma were at increased risk for thrombotic events (HR: 4.22; 95%CI: 1.25-14.3). Conclusions: Major bleeding in VTE patients receiving VKA carries a high mortality rate. Intracranial bleeding and renal insufficiency increased the risk. Fresh frozen plasma seems to increase this risk for recurrent VTE.
  • Some of the metrics are blocked by your 
    Item type:Publication,
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Recurrent Severe Hepatitis of Autoimmune Origin
    (Macedonian Academy of Sciences and Arts / Sciendo, 2021-04-23)
    ;
    ;
    ;
    Serafimovski, Vladimir
    The autoimmune liver disease constituent conditions include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and IgG-4 associated cholangitis. They remain a diagnostic challenge to the practicing physician due to their close resemblance in clinical course, and laboratory and imaging findings to the vast array of other etiologies of liver injury. We report a case of recurrent severe hepatitis of autoimmune origin in a female patient. The disease course was marked by initial onset at age 39, followed by nearly four years of remission, and a second flare with a more exaggerated severity. Systemic lupus erythematosus was initially deemed as the culprit, however formal diagnostic criteria were not fulfilled and the serological findings were not reproduced at a later date. With the aim of ascertaining the underlying process, the patient underwent an extensive array of testing with regards to infectious, genetic, systemic and autoimmune disease. Positive anti-dsDNA (double stranded DNA) and an antinuclear antibody titer of 1:160 provided the strongest support for an autoimmune etiology, specifically autoimmune hepatitis or possibly an overlap syndrome. An excellent outcome was achieved via treatment with corticosteroids, ursodeoxycholic acid and plasmapheresis.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Nutrition in Advanced Age Population
    (Consulting and Training Center KEY, 2021-09)
    ;
    Nutritional status of an individual is affected by genetic and environmental factors, access to nutrients, personal preferences, nutritional awareness, comorbidities and daily habits. The number of individuals aged over 65 is increasing globally. This review will look at strategies for nutritional screening and diet therapy in the elderly, taking into account phenomena that influence nutrition and commonly affect this age group. Malnutrition can be assessed via criteria that account for loss of weight, muscle and subcutaneous fat, in combination with decreased energy intake and functional status. Malnutrition and involuntary weight loss are associated with an increased mortality risk, while some studies show that voluntary weight loss reduces this risk. Malnutrition leads to a plethora of negative outcomes, and may signal dire underlying disease such as malignancy. Factors that predispose to malnutrition in the elderly include: anatomical and physiological changes of the gastrointestinal tract, endocrine system and body composition, and impairment of sight, smell and taste. Concomitant illnesses affecting the heart, lungs, liver and kidneys, and depression and dementia also negatively impact nutrition, while socio-economic changes interfere with access to food. Once identified, malnutrition can be mitigated via diet therapy which aims to tailor nutrition to the aforementioned changes, compensate any deficiencies and prevent future recurrence. Special attention should be paid to caloric, protein and fat requirements and diet supplementation with vitamin D, B12, iron and calcium. Focused nutritional assessment can aid in timely detection of malnutrition and its constituent components, which include anorexia, cachexia and sarcopenia. This also provides the opportunity to identify underlying malignancy, and systemic and psychiatric conditions. Diet therapy can then be tailored to accommodate for these conditions and to the changes known to occur in the elderly, potentially mitigating malnutrition and reducing mortality risk.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Frequency of CYP2D6*3 Allele in Macedonian Population - Pilot Study
    (2011-11)
    ;
    Senev, Aleksandar
    ;
    ;
    Background. The cytochrome P450 enzymes are members of an isoenzyme superfamily that catalyzes the oxidation of many drugs and chemicals. Genetic polymorphisms have been identified for some of the CYP450 enzyme genes that alter enzyme activity. Depending on gene variations, individuals may be intermediate metabolizers (IMs) or poor metabolizers (PMs) or ultra-rapid metabolizers (UMs). CYP2D6 is responsible for the metabolism of environmental chemicals and drugs such as: antiarrhythmics, adenoreceptor antagonists and tricyclic antidepressants. Methods: Thirty-eight volunteers of Macedonian origin previously involved in pahrmacokynetic studies at the institute of Pharmacology and Toxicology were recruited for this study. After signing written consent, DNA was isolated using the phenol-chlorophorm procedure and stored at the human DNA bank (hDNAMKD) at the Institute of Immunobiology and Human Genetics. The exon 5 of the CYP2D6 gene was PCR amplified in order to confirm the presence of the allele # 3 of the 2D6 gene. The resulting product was then digested with the enzyme MspI. Next, electrophoretic separation on the Multiphor II using 12.5% polyacrilamide gel and silver staining was performed. Results: The results indicated that of the 38 samples analyzed with the polyacrylamide gel electrophoresis, 37 portrayed a normal homozygote genotype while only 1 sample showed heterozygous genotypic pattern. Therefore, the frequency of 2D6*3 heterozygotes in the 38 studied samples is 2.6%. This finding is comparable with the other European populations upon which this study has been done. Conclusion: To our knowledge, this is the first study analyzing genetic polymorphism of the CYP2D6 gene in the Macedonian population. In this study we present preliminary results, with the goal to continue and eventualy analyze a representative number of samples which would make comparisons with other European populations possible.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Value of Injection Therapy with Botulinum Toxin in Pain Treatment of Primary Chronic Anal Fissures Compared to Anal Dilation, and Local Nifedipine in Combination with Lidocaine
    (Македонска академија на науките и уметностите, Одделение за медицински науки = Macedonian Academy of Sciences and Arts, Section of Medical Sciences/Sciendo, 2023-07-01)
    ;
    ;
    ;
    ;
    Introduction: Anal fissure is a longitudinal tear of the mucosa of the anal canal extending from the outer anal orifice in the direction of the dentate line of the inner anal opening. Fissures are divided into primary and secondary, and acute or chronic. Besides minimal rectal bleeding, itching and soiling, primary chronic anal fissures (PCAF) manifest with anal pain as theirs main determinant. It is described as the most troubling symptom. Aim: To compare the effect of injection therapy with botulinum toxin A (ITBT) vs. anal dilation (AD), and local nifedipine with lidocaine (LNL) in pain treatment of PCAF. Materials and Methods: This controlled retrospective prospective longitudinal study covered 94 patients, divided in 3 groups. The first was treated with ITBT, the second with AD and third using LNL (31, 33 and 30 patients respectively). Clostridium botulinum toxin A was used, dissolved with saline to concentration of 200 U/ml. The solution was applied to both sides of PCAF at dose of 40U. Modified technique of AD was done using 3 fingers of a single hand, progressively introduced into the anal canal, followed by gradual lateral distraction during 1 min. LNL therapy was conducted using nifedipine (0.3%) with lidocaine (1.5%) ointment, applied twice daily for 3 weeks. To measure pain, a visual analog scale (VAS) was used. The follow-up period was 12 weeks with checkup at week 4. Results: The median age of participants was 46.6±13.9 years (50 males vs. 44 females). The type of therapy had a significantly different effect on pain at week 4 (p=0.0003). Severe pain was present in only 2 ITBT patients, 16 AD, and 6 LNL patients. Post hoc analyses showed different pain disappearance time by week 12 (p <0.0001). The mean time was shortest in ITBT group (6.1±1.5 weeks). Anal pain intensity significantly differed among the 3 groups (Fisher exact, p=0.002). Namely, 71% in ITBT group rated the pain as weakest (VAS score 1) compared to 18.2% in AD and 30% of patients in LNL group. The overall pain reduction significance was in favor of ITBT, due to the differences between the ITBT and AD groups (p=0.00024) and ITBT compared to LNL group (p=0.018). Conclusion: ITBT is superior to AD and LNL in reducing pain in PCAF.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Crohn's Disease and Ulcerative Colitis - Diferential Diagnosis and Treatment
    (Macedonian Association of Internal Medicine, 2022-05)
    ;
    ;
    ;
    Pejkovski, Stefan
    ;
    INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) are the two main forms of chronic inflammatory bowel diseases (IBD) on the rise in the few past decades, particularly CD. May present at any age, but peak incidence is in adolescents and young adults. These disorders have distinct pathologic and clinical characteristics, but they have almost same burden and goals for treatment. OBJECTIVES: To analyze the differential diagnostic features and assessment of both diseases and up to date treatment modalities worldwide with special attention on current therapeutic opportunities in Macedonia. METHODS: This is as a general, practice-oriented overview concerning differential diagnosis and management of CD versus UC, mainly based on expert groups and international society's guidelines (IOIBD, ECCO, AGA, and ACG), meta-analysis and our personal experience. RESULTS: We analyze not only similarities between CD and UC, including effects on quality of life, long-term complications, strictures, increased risk of cancer, pseudo polyposis, functional abnormalities, and anorectal dysfunction, but also differences linked to a distribution (entire GI tract vs colon only and skip lesions vs continuous involvement from rectum); pathology (full thickness and granuloma in CD vs mucosa only and no granulomas in UC) and presentation (occasional bleeding, common obstruction, fistulae formation, weight loss and perianal disease in CD vs very common bleeding, uncommon obstruction and weight loss, none fistulae formation and rare perianal disease in UC). Regardless of severity of the disease and the period when it is used (early vs late stages) and whether it is a part from bottom up or top down approach, IBD therapy consists of the use of aminosalicylates, antibiotics, steroids, immunosuppressives and biologics. Currently, 35 patients are being treated with biologic therapy at our institution. Five are treated with JAK inhibitor and the rest of them with anti TNF agents (biologics and biosimilars). CONCLUSION: A cure is still not possible, neither for CD nor for UC, yet the opportunities for diagnosis and management have improved significantly. Early diagnosis is a cornerstone, so that patients can be referred for further evaluation and appropriate treatment in timely manner. Earlier initiation of disease-modifying drugs might reduce progression and their burden. The number of treatment options in IBD patients is increasing constantly. Biologic therapy is available in Macedonia. New therapeutic opportunities redefine the therapeutic goals, with treat to target been the most relevant strategy. We work with our patients to improve treatment opportunities, taking patient preference and personal goals into consideration, whenever possible.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry
    (2019)
    Martin Murgier,
    ;
    Laurent Bertoletti,
    ;
    Michael Darmon,
    ;
    Fabrice Zeni,
    ;
    Reina Valle,
    Rationale: Acute kidney injury (AKI) is associated with a poor outcome. Although pulmonary embolism (PE) may promote AKI through renal congestion and/or hemodynamic instability, its frequency and influence on outcome in patients with acute PE have been poorly studied. Methods: The frequency of AKI (defined according to the "Kidney Disease: Improving Global Outcomes" definition) at baseline and its influence on the 30-day mortality was evaluated in patients with acute PE from the RIETE (Registro Informatizado Enfermedad TromboEmbolica) registry. We used multivariate analysis to assess whether the presence of AKI influenced the risk for 30-day death. Results: The study included 21,131 patients, of whom 6222 (29.5%) had AKI at baseline: 4385 patients (21%) in stage 1, 1385 (6.5%) in stage 2 and 452 (2%) in stage 3. The proportion of patients with high-risk PE in those with no AKI, AKI stage 1, AKI stage 2 or AKI stage 3 was: 2.8%, 5.3%, 8.8% and 12%, respectively (p < 0.001). After 30 days, 1236 patients (5.9%) died. Overall mortality was 4% in patients with no AKI, 8.4% in AKI stage 1, 14% in AKI stage 2 and 17% in AKI stage 3 (all p < 0.001). AKI was independently associated with an increased risk of all-cause death at 30 days (odds ratio = 1.25; 95%CI: 1.02-1.54). Conclusions: One in every 3-4 patients with acute PE had AKI at baseline. The presence of AKI independently predicted 30-day mortality. This study suggests that AKI may deserve to be evaluated as a prognostic factor in patients with acute PE.